XML 33 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2017
Summary of Significant Accounting Policies  
Schedule of receivables from maximum payments from collaborative partners and licensees

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Potential Milestones (in millions)

 

 

    

 

 

    

 

 

    

 

 

    

Total

 

Partner

 

Development-based

 

Regulatory-based

 

Sales-based

 

Milestones

 

Alexion (1)

 

$

 —

 

$

28.0

 

$

30.0

 

$

58.0

 

Amgen

 

 

222.5

 

 

345.0

 

 

1,080.0

 

 

1,647.5

 

BI (1)

 

 

9.0

 

 

6.0

 

 

12.0

 

 

27.0

 

CSL Janssen 2009 (1)

 

 

 —

 

 

4.0

 

 

5.0

 

 

9.0

 

Janssen (1)

 

 

6.0

 

 

 —

 

 

4.0

 

 

10.0

 

MorphoSys (1)

 

 

49.5

 

 

187.0

 

 

50.0

 

 

286.5

 

Novartis

 

 

540.0

 

 

920.0

 

 

950.0

 

 

2,410.0

 

Total

 

$

827.0

 

$

1,490.0

 

$

2,131.0

 

$

4,448.0

 


(1)

The payments are solely dependent upon activities of the collaborative partner or licensee.

Schedule of revenue by licensees

The $35.7 million, $87.5 million and $27.8 million of revenue recorded for the years ended December 31, 2017, 2016 and 2015, respectively, was earned principally from the following licensees (in millions):

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended

 

 

 

December 31, 

 

 

 

2017

 

2016

 

2015

 

Amgen

    

$

16.2

    

$

18.7

    

$

13.8

 

Alexion

 

 

1.0

 

 

6.0

 

 

8.5

 

MorphoSys

 

 

 12.5

 

 

 —

 

 

 —

 

Novo Nordisk

 

 

 —

 

 

2.7

 

 

2.9

 

Novartis

 

 

2.3

 

 

59.7

 

 

 —

 

CSL

 

 

3.5

 

 

 —

 

 

2.5

 

Other

 

 

0.2

 

 

0.4

 

 

0.1

 

Total

 

$

35.7

 

$

87.5

 

$

27.8

 

 

Schedule of revenue from U.S. and Non U.S. sources

A breakdown of our revenue from U.S. and Non‑U.S. sources for the years ended December 31, 2017, 2016 and 2015 is as follows (in millions):

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended

 

 

 

December 31, 

 

 

    

2017

    

2016

    

2015

 

U.S. Revenue

 

$

19.7

 

$

84.8

 

$

22.4

 

Non-U.S. Revenue

 

 

16.0

 

 

2.7

 

 

5.4

 

Total

 

$

35.7

 

$

87.5

 

$

27.8

 

 

Schedule of assets recorded at fair value

The Company measures the fair value of financial assets using the highest level of inputs that are reasonably available as of the measurement date. The assets recorded at fair value are classified within the hierarchy as follows for the periods reported (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2017

 

    

Total

    

 

 

 

 

 

 

    

Fair Value

    

Level 1

    

Level 2

 

 

 

 

 

 

 

 

 

 

Money Market Funds in Cash and Cash Equivalents

 

$

5,175

 

$

5,175

 

$

 —

Corporate Securities

 

 

123,270

 

 

 —

 

 

123,270

Government Securities

 

 

223,530

 

 

 —

 

 

223,530

 

 

$

351,975

 

$

5,175

 

$

346,800

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2016

 

    

Total

    

 

 

 

 

 

 

 

Fair Value

 

Level 1

 

Level 2

 

 

 

 

 

 

 

 

 

 

Money Market Funds in Cash and Cash Equivalents

 

$

12,137

 

$

12,137

 

$

 —

Corporate Securities

 

 

181,483

 

 

 —

 

 

181,483

Government Securities

 

 

207,465

 

 

 —

 

 

207,465

 

 

$

401,085

 

$

12,137

 

$

388,948

 

Schedule of useful lives by asset category

 

 

 

 

 

    

    

 

Computers, software and equipment

 

3 - 5 years

 

Furniture and fixtures

 

5 - 7 years

 

Leasehold improvements

 

5 - 7 years or remaining

 

 

 

lease term, whichever is less

 

 

Schedule of indefinite-lived intangible assets

The carrying amount and accumulated amortization of patents, licenses, and other intangibles is as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

December 31, 

 

 

    

2017

    

2016

 

Patents, definite life

 

$

8,915

 

$

7,570

 

Patents, pending issuance

 

 

4,360

 

 

4,134

 

Licenses and other amortizable intangible assets

 

 

2,011

 

 

2,011

 

Nonamortizable intangible assets (trademarks)

 

 

399

 

 

399

 

Total gross carrying amount

 

 

15,685

 

 

14,114

 

Accumulated amortization—patents

 

 

(3,413)

 

 

(2,792)

 

Accumulated amortization—licenses and other

 

 

(1,124)

 

 

(960)

 

Total intangible assets, net

 

$

11,148

 

$

10,362

 

 

Future amortization expense for patents, licenses, and other intangible assets

 

 

 

 

 

 

    

Year ended

 

 

    

December 31, 

 

 

 

(in thousands)

 

2018

 

$

838

 

2019

 

 

827

 

2020

 

 

780

 

2021

 

 

704

 

2022

 

 

676

 

Thereafter

 

 

2,364

 

Total

 

$

6,189

 

 

Schedule of potentially dilutive securities

 

 

 

 

 

 

 

 

 

 

Year Ended

 

 

 

December 31, 

 

 

    

2017

    

2016

    

2015

 

 

 

(in thousands)

 

Options to purchase common stock

 

1,291

 

 —

 

1,281

 

Employee stock purchase plan shares

 

 —

 

 —

 

75

 

Total

 

1,291

 

 —

 

1,356

 

 

Schedule of basic and diluted net income (loss) per common share

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31, 

 

 

 

2017

 

2016

 

2015

 

 

 

(in thousands, except

 

 

 

share and per share data)

 

Basic

    

 

    

    

 

    

    

 

    

 

Numerator:

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to common stockholders for basic net income (loss) per share

 

$

(48,925)

 

$

23,625

 

$

(17,592)

 

Denominator:

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

46,817,756

 

 

41,267,329

 

 

39,015,131

 

Basic net income (loss) per common share

 

$

(1.05)

 

$

0.57

 

$

(0.45)

 

Diluted

 

 

 

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to common stockholders for diluted net income (loss) per share

 

$

(48,925)

 

$

23,625

 

$

(17,592)

 

Denominator:

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding used in computing basic net income (loss) per common share

 

 

46,817,756

 

 

41,267,329

 

 

39,015,131

 

Dilutive effect of employee stock options and ESPP

 

 

 —

 

 

1,121,538

 

 

 —

 

Weighted-average number of common shares outstanding used in computing diluted net income (loss) per common share

 

 

46,817,756

 

 

42,388,867

 

 

39,015,131

 

Diluted net income (loss) per common share

 

$

(1.05)

 

$

0.56

 

$

(0.45)